Digestive System Neuroendocrine Carcinoma

general

An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the digestive system. It is composed of malignant small or large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20% (often more than 70%).

65

Centers

259

Active Trials

$18.0B

Cancer Funding

Specific Cancer Types(4)

Top Centers for Digestive System Neuroendocrine Carcinoma(65)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
2
NCI Comprehensive
3
4
5
NCI Comprehensive
6
NCI Comprehensive
7
NCI Comprehensive
8
NCI Comprehensive
9
NCI Comprehensive
10
NCI Comprehensive
11
NCI Comprehensive
12
NCI Comprehensive
13
NCI Comprehensive
14
15
NCI Comprehensive
16
17
18
19
NCI Comprehensive
20
21
Masonic Cancer CenterMinneapolis, MN
NCI Comprehensive
22
23
NCI Comprehensive
24
NCI Comprehensive
25
NCI Comprehensive
26
NCI Comprehensive
27
NCI Comprehensive
28
NCI Comprehensive
29
NCI Clinical
30
31
NCI Comprehensive
32
NCI Comprehensive
33
NCI Comprehensive
34
35
36
NCI Comprehensive
37
38
Cedars-Sinai CancerLos Angeles, CA
39
NCI Comprehensive
40
41
42
43
NCI Comprehensive
44
NCI Comprehensive
45
46
47
48
49
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
50
51
NCI Comprehensive
52
53
54
55
56
NCI Basic_laboratory
57
58
59
60
61
62
63
64
65

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →